Table 3.
Comparing differences between men experiencing no toxicity (Grade 1) with those experiencing significant (Grade 4) vasomotor symptoms (VMS).
| Variables | No VMS-Grade 1 n = 50 (%) | Severe VMS-Grade 4 n = 29 (%) | Statistics (t-test/chi squared)* | p value |
|---|---|---|---|---|
| Age (year)(mean ± SD) | 77.12 ± 7.56 | 73.10 ± 8.84 | 2.14 | 0.04 |
| Height (m)(mean ± SD) | 171.08 ± 7.25 | 172.34 ± 6.66 | -0.77 | 0.44 |
| Weight (Kg)(mean ± SD) | 76.98 ± 12.85 | 83.20 ± 11.05 | -2.18 | 0.03 |
| Body Mass Index (mean ± SD) | 26.18 ± 3.23 | 28.10 ± 3.78 | -2.40 | 0.02 |
| BSA (mean ± SD) | 1.90 ± 0.19 | 1.99 ± 0.15 | -2.14 | 0.04 |
| PSA (mean ± SD) | 316.94 ± 1490.83 | 156.6 ± 368.29 | 0.55 | 0.59 |
| Ethnicity (n, %) | ||||
| Afrocarribean | 23 (47.92) | 18 (66.67) | 2.62 | 0.27 |
| Asian | 9 (18.75) | 4 (14.81) | ||
| Caucasian | 16 (33.33) | 5 (18.52) | ||
| Hormone treatment (n, %) | ||||
| LHRH | 36 (72) | 18 (62.07) | 0.84 | 0.36 |
| Others | 14 (28) | 11 (37.93) | ||
| Treatment time (n, %) | ||||
| <=6 months | 23 (46) | 14 (48.28) | 0.04 | 0.85 |
| >6 months | 27 (54) | 15 (51.72) | ||
| Stage of illness (n, %) | ||||
| N0 & M0 | 30 (66.67) | 16 (59.26) | 0.40 | 0.53 |
| N1 and/or M1 | 15 (33.33) | 11 (40.74) | ||
| Diabetes (n, %) | ||||
| Yes | 11 (23.40) | 10 (35.71) | 1.32 | 0.25 |
| No | 36 (76.60) | 18 (64.29) | ||
| IHD (n, %) | ||||
| Yes | 18 (38.30) | 7 (25) | 1.40 | 0.24 |
| No | 29 (61.70) | 21 (75) | ||
| BP (n, %) | ||||
| Yes | 23 (48.94) | 18 (64.29) | 1.67 | 0.20 |
| No | 24 (51.06) | 10 (35.71) |
SD = standard deviation-t-test numerical variable, chi squared – categorical data.
*
Chi-square test for categorical variables and t-test for continuous variables.